(Corrects date of Chimerix case to 2014 from 2013)
By Sharon Begley
NEW YORK, May 7 (Reuters) - Johnson & Johnson will become the first pharmaceutical company to formally seek advice from outside medical ethicists on “compassionate use” requests, in which desperate patients ask drugmakers to let them take an experimental medication, the company announced on Thursday.
The ethicists’ recommendations will be advisory, with J&J making the decision.
But the drugmaker must “give us a rationale if they disagree,” said bioethicist Arthur Caplan of NYU School of Medicine, who will lead the committee of 10 and recommended the approach to J&J. “I don’t think we’d keep doing this if they kept ignoring us.”
Some ethicists said they were concerned because J&J does not plan to disclose the advisors’ recommendations to the public.
“I’d like to think this is a well-meaning way to make compassionate-use decisions as objective as possible,” said Craig Klugman of DePaul University. “But my cynical side says it gives the company another way to say no.”
Compassionate-use requests can put a drugmaker in an unwelcome spotlight, casting it as heartless.
In 2014, doctors treating a 7-year-old with a potentially-fatal infection asked Chimerix Inc. to provide its investigational anti-viral brincidofovir to the boy. After the company declined twice, the family mounted a campaign on social media, causing Chimerix to be barraged with phone calls and emails pleading the boy’s case.
After intense media coverage, Chimerix relented, the board replaced the chief executive officer, and the boy got the drug. He recovered.
Although it might seem that patients with no other options should have access to experimental drugs, that can come at a cost. Since such drugs are typically in short supply, diverting some from clinical trials “could delay an effective drug from reaching the market and helping other patients,” Klugman said.
J&J hopes to make such decisions less dependent on which patients have influential politicians or social-media savvy on their side.
“These are some of the most difficult decisions we face,” said Dr. Amrit Ray, chief medical officer of J&J’s Janssen Pharmaceuticals unit, which has received “hundreds” of compassionate-use requests over the years. He did not specify which drugs had been requested.
The bioethics committee will consider only requests for a Janssen medicine currently in a late-stage clinical trial. The company declined to identify it. If the pilot succeeds, said Ray, it will expand to requests for other drugs.
The committee will be able to convene rapidly to consider urgent requests. In an emergency, such as if a patient has days to live, Caplan will make the recommendation. (Reporting by Sharon Begley; Editing by David Gregorio)